Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1143-1145

  Pae, Chi Un ^a,b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Korean; Mirtazapine; Nausea; Vomiting

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; DIMENHYDRINATE; ELECTROLYTE; METOCLOPRAMIDE; MIRTAZAPINE;

ABDOMINAL CRAMP; ADULT; AGITATION; ANOREXIA; ARTICLE; ASIAN; CASE REPORT; DEPRESSION; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; ELECTROLYTE INTAKE; FEMALE; FLUID THERAPY; GASTRITIS; HUMAN; HYDRATION; KOREA; LACRIMATION; LOW DRUG DOSE; NAUSEA AND VOMITING; SEDATION; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIEMETICS; DEPRESSIVE DISORDER; HUMANS; KOREA; MALE; MIANSERIN; NAUSEA; VOMITING;

EID: 33745228117     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.03.015     Document Type: Article

References (12)

1. Caldis E.V., and Gair R.D. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors. Can J Psychiatry 49 (2004) 707
2. Fuiji Y. The utility of antiemetics in the prevention and treatment of postoperative nausea and vomiting in patients scheduled for laparoscopic cholecystectomy. Curr Pharm Des 11 (2005) 3173-3183
3. Grasmader K., Verwohlt P.L., Kuhn K.U., Dragicevic A., von Widdern O., Zobel A., et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 60 (2004) 473-480
4. Homby P.J. Central neurocircuitry associated with emesis. Am J Med 111 Suppl 8A (2001) 106S-112S
5. Kim K., Johnson J.A., and Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44 (2004) 1083-1105
6. Minami M., Endo T., Hirafuji M., Hamaue N., Liu Y., Hiroshige T., et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 99 (2003) 149-165
7. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 391 (1997) 31-37
8. Pedersen L., and Klysner R. Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Int Clin Psychopharmacol 12 (1997) 59-60
9. Rohde A., Dembinski J., and Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstetd 268 (2003) 219-221
10. Teixeira F.V., Novaretti T.M., Pilon B., Pereira P.G., and Breda M.F. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg 15 (2005) 707-709
11. Theobald D.E., Kirsh K.L., Holtsclaw E., Donaghy K., and Passik S.D. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23 (2002) 442-447
12. Thompson D.S. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41 (2000) 356-369